
ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.

Lawrence Leiter, MD, is the director of the Lipid Clinic; associate director of the Clinical Nutrition and Risk Factor Modification Centre; associate scientist, Li Ka Shing Knowledge Institute at St. Michael’s Hospital; and professor in the departments of medicine and nutritional sciences at the University of Toronto.

ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.